Allogeneic Eng gd eTCR Tcell therapy (Immatics/Brostol-Myers Squibb)

N/A

Report date: 2023/12/15 17:53:24

Base Information

Drug NameAllogeneic Eng gd eTCR Tcell therapy (Immatics/Brostol-Myers Squibb)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmatics NV Bristol-Myers Squibb Company

China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company Immatics NV

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A